492 related articles for article (PubMed ID: 24491679)
1. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
[TBL] [Abstract][Full Text] [Related]
2. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2018; 9():612. PubMed ID: 29670616
[TBL] [Abstract][Full Text] [Related]
3. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
4. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
Aradottir SS; Kristoffersson AC; Roumenina LT; Bjerre A; Kashioulis P; Palsson R; Karpman D
Front Immunol; 2021; 12():690821. PubMed ID: 34177949
[TBL] [Abstract][Full Text] [Related]
5. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome.
Martínez-Barricarte R; Heurich M; López-Perrote A; Tortajada A; Pinto S; López-Trascasa M; Sánchez-Corral P; Morgan BP; Llorca O; Harris CL; Rodríguez de Córdoba S
Mol Immunol; 2015 Aug; 66(2):263-73. PubMed ID: 25879158
[TBL] [Abstract][Full Text] [Related]
6. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
[TBL] [Abstract][Full Text] [Related]
7. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
Blanc C; Togarsimalemath SK; Chauvet S; Le Quintrec M; Moulin B; Buchler M; Jokiranta TS; Roumenina LT; Fremeaux-Bacchi V; Dragon-Durey MA
J Immunol; 2015 Jun; 194(11):5129-38. PubMed ID: 25917093
[TBL] [Abstract][Full Text] [Related]
8. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.
Togarsimalemath SK; Sethi SK; Duggal R; Le Quintrec M; Jha P; Daniel R; Gonnet F; Bansal S; Roumenina LT; Fremeaux-Bacchi V; Kher V; Dragon-Durey MA
Kidney Int; 2017 Oct; 92(4):876-887. PubMed ID: 28729035
[TBL] [Abstract][Full Text] [Related]
9. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
[TBL] [Abstract][Full Text] [Related]
10. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.
Michels MAHM; van de Kar NCAJ; Volokhina EB; van den Heuvel BLPWJ
Methods Mol Biol; 2021; 2227():83-96. PubMed ID: 33847933
[TBL] [Abstract][Full Text] [Related]
11. Anti-factor B autoantibody in dense deposit disease.
Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
[TBL] [Abstract][Full Text] [Related]
12. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
13. Genetics of atypical hemolytic uremic syndrome (aHUS).
Rodríguez de Córdoba S; Hidalgo MS; Pinto S; Tortajada A
Semin Thromb Hemost; 2014 Jun; 40(4):422-30. PubMed ID: 24799305
[TBL] [Abstract][Full Text] [Related]
14. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.
Corvillo F; Okrój M; Nozal P; Melgosa M; Sánchez-Corral P; López-Trascasa M
Front Immunol; 2019; 10():886. PubMed ID: 31068950
[TBL] [Abstract][Full Text] [Related]
15. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
Subías M; Tortajada A; Gastoldi S; Galbusera M; López-Perrote A; Lopez Lde J; González-Fernández FA; Villegas-Martínez A; Dominguez M; Llorca O; Noris M; Morgan BP; Rodríguez de Córdoba S
J Immunol; 2014 Dec; 193(11):5567-75. PubMed ID: 25355917
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles.
Skerka C; Licht C; Mengel M; Uzonyi B; Strobel S; Zipfel PF; Józsi M
Mol Immunol; 2009 Sep; 46(14):2801-7. PubMed ID: 19640589
[TBL] [Abstract][Full Text] [Related]
17. Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.
Song D; Yu XJ; Wang FM; Xu BN; He YD; Chen Q; Wang SX; Yu F; Song WC; Zhao MH
Am J Reprod Immunol; 2015 Oct; 74(4):345-56. PubMed ID: 26011580
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients.
Mohlin FC; Nilsson SC; Levart TK; Golubovic E; Rusai K; Müller-Sacherer T; Arbeiter K; Pállinger É; Szarvas N; Csuka D; Szilágyi Á; Villoutreix BO; Prohászka Z; Blom AM
Mol Immunol; 2015 Jun; 65(2):367-76. PubMed ID: 25733390
[TBL] [Abstract][Full Text] [Related]
19. Atypical aHUS: State of the art.
Nester CM; Barbour T; de Cordoba SR; Dragon-Durey MA; Fremeaux-Bacchi V; Goodship TH; Kavanagh D; Noris M; Pickering M; Sanchez-Corral P; Skerka C; Zipfel P; Smith RJ
Mol Immunol; 2015 Sep; 67(1):31-42. PubMed ID: 25843230
[TBL] [Abstract][Full Text] [Related]
20. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.
Valoti E; Alberti M; Iatropoulos P; Piras R; Mele C; Breno M; Cremaschi A; Bresin E; Donadelli R; Alizzi S; Amoroso A; Benigni A; Remuzzi G; Noris M
Front Immunol; 2019; 10():853. PubMed ID: 31118930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]